A downtrend has been apparent in Supernus Pharmaceuticals (SUPN) lately with too much selling pressure. The stock has ...

NEW YORK, NY / ACCESS Newswire / March 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Supernus ...

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results ...

We recently compiled a list of the 10 Cash-Rich Small Cap Stocks To Invest In According To Analysts. In this article, we are going to take a look at where Supernus Pharmaceuticals, Inc.

StockNews.com upgraded shares of Supernus Pharmaceuticals (NASDAQ:SUPN – Free Report) from a buy rating to a strong-buy rating in a report published on Sunday morning. Separately, Cantor Fitzgerald ...

Highlights,Smartleaf Asset Management LLC increased its stake in Supernus Pharmaceuticals, reflecting growing institutional ...

Supernus Pharmaceuticals (SUPN) reported $174.16 million in revenue for the quarter ended December 2024, representing a year-over-year increase of 6%. EPS of $0.75 for the same period compares to ...

Ritz-Carlton South Beach, Miami, Fla. Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.

ROCKVILLE, Md. (AP) — ROCKVILLE, Md. (AP) — Supernus Pharmaceuticals Inc. (SUPN) on Tuesday reported fourth-quarter earnings of $15.3 million. On a per-share basis, the Rockville, Maryland ...

About Supernus Pharmaceuticals, Inc. Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS ...